Publications by authors named "K A Brownley"

Article Synopsis
  • - This study aimed to identify biomarkers related to anorexia nervosa (AN) by analyzing data from various published studies up to mid-2022.
  • - It found that certain biomarkers, like acylated ghrelin and cortisol, were significantly higher in individuals with AN, while others, such as leptin and insulin, were lower compared to non-AN controls.
  • - The findings suggest that these peripheral biomarkers could be important for understanding the biological mechanisms behind AN and might lead to improved personalized treatments in the future.
View Article and Find Full Text PDF

Binge eating is a transdiagnostic eating disorder symptom that can occur in patients with anorexia nervosa (AN), persisting after weight restoration, and impeding their recovery. However, little is known about the biological predictors of binge eating after AN weight restoration. The goals of this exploratory study of 73 females with AN were: (1) to examine changes in cortisol, the adrenocorticotropic hormone, norepinephrine, ghrelin (total and active), and leptin levels across the admission, discharge, and 3 months post-discharge from the inpatient AN weight restoration; and (2) to determine whether the target hormones were associated with objective or subjective binge eating (OBE or SBE).

View Article and Find Full Text PDF

In this paper, we address how the COVID-19 pandemic has impacted informed consent for clinical research through examining experiences within Clinical and Translation Science Award (CTSA) institutions. We begin with a brief overview of informed consent and the challenges that existed prior to COVID-19. Then, we discuss how informed consent processes were modified or changed to address the pandemic, consider what lessons were learned, and present research and policy steps to prepare for future research and public health crises.

View Article and Find Full Text PDF

Availability of trained professionals to assist researchers navigating regulatory pathways for new drug and device development is limited within academic institutions. We created ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices), a regional forum initially involving regulatory professionals from four Clinical and Translational Science Award (CTSA)-funded institutions, to build and capitalize on local expertise and to develop a regulatory guidance website geared toward academic researchers. Since 2015, members organized 15 forums covering topics such as FDA premarket submissions, gene therapy, and intellectual property for devices and therapeutics.

View Article and Find Full Text PDF